Komori
Tsubota Laboratory (4890) · RiskMitigatedLatest Governance (2026-06-25): "Restated"

Risk of Concentration among Major Shareholders and Declining Stock Liquidity

First written in FY2022. 4 of 6 entries say "Mitigated", first in FY2023. Latest entry: 2026-06-25.

6entries
5years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022MitigatedFY2023 – FY20262022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Risk of declining share liquidity due to concentration among representative shareholdersA theme 13 companies write about · 13 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 1 of 10 companies on the "Worse" side.

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-06-25RestatedGovernance

    「Kazuo Tsubota 46.23 14.69 60.92 ―」

    Under matters concerning the controlling shareholder, the company reported Kazuo Tsubota’s voting-rights ownership as 46.23% directly and 60.92% in aggregate. The figures reconfirm existing disclosures, and the company stated that there were no applicable transactions with the controlling shareholder.
  2. FY2026MitigatedAnnual report

    「As of the end of the current fiscal year, Tsubota Kazuo (坪田一男) held 46.23% of the voting rights directly. The combined ownership of the voting rights held by Tsubota Co., Ltd., Tsubota Kazuo's (坪田一男) asset management company, and blood relatives within the second degree was 60.92%, and he is expected to remain a major shareholder.」

    The founder's direct ownership was 46.23%, while the combined ownership of related parties was 60.92%. The free-float ratio rose to 33.57%, showing the improvement in liquidity numerically.
  3. FY2026-H1MitigatedAnnual report

    「Tsubota Kazuo (坪田 一男) 11,923,700 46.23」

    The direct ownership of the representative director and founder declined from 49.25% at the end of March 2025 to 46.23%, further reducing the numerical concentration of share ownership.
  4. FY2024MitigatedAnnual report

    「As of the end of the current fiscal year, Tsubota Kazuo (坪田一男) held 49.25% of the voting rights directly. The combined ownership of the voting rights held by Tsubota Co., Ltd., Tsubota Kazuo's (坪田一男) asset management company, and blood relatives within the second degree was 64.06%.」

    The founder's direct ownership declined from 50.90% in the previous fiscal year to 49.25%, while the combined ownership of related parties declined from 65.81% to 64.06%. The free-float ratio was 30.90%.
  5. FY2023MitigatedAnnual report

    「As of the end of the current fiscal year, Tsubota Kazuo (坪田一男) held 50.90% of the voting rights directly. The combined ownership of the voting rights held by Tsubota Co., Ltd., Tsubota Kazuo's (坪田一男) asset management company, and blood relatives within the second degree was 65.81%.」

    The founder's direct ownership declined from 53.79% to 50.90%, while the combined ownership of related parties declined from 68.72% to 65.81%. The free-float ratio rose from 27.24% to 30.01%, indicating a numerical reduction in concentration and liquidity risks.
  6. FY2022First statedAnnual report

    「As of the date of filing this document, Tsubota Kazuo (坪田一男) held 53.79% of the voting rights directly. The combined ownership of the voting rights held by Tsubota Co., Ltd., Tsubota Kazuo's (坪田一男) asset management company, and blood relatives within the second degree was 68.72%.」

    The disclosure also shows a free-float ratio of 27.24% and states a policy of improving liquidity through secondary offerings, public offerings and the exercise of stock options.
Moved together

"Commercialization of R&D Pipelines and Establishment of Post-Launch Royalty Revenue" moved the same way as this thread, in the same document, in 3 of its 6 moves.

333332★123456
  1. ★This thread
  2. 1Commercialization of R&D Pipelines and Establishment of Post-Launch Royalty Revenue3×
  3. 2Strengthening basic research3×
  4. 3Expansion of the research collaboration framework within and outside Keio University3×
  5. 4Expanding partnerships with leading companies in Japan and overseas3×
  6. 5Clinical Trial and Launch of TLM-003 Myopia Progression Prevention Eye Drops3×
  7. 6Global Out-Licensing and Royalty Monetization of TLM-001, a Treatment for Meibomian Gland Dysfunction2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tsubota Laboratory yet. It last moved in the Governance of 2026-06-25: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Concentration among Major Shareholders and Declining Stock Liquidity | Tsubota Laboratory Incorporated (4890) | Komori